Reported 3 days ago
Jim Cramer recently discussed Abbott Laboratories (ABT), noting its 16.7% share growth year-to-date despite a dip following mixed Q2 earnings. He expressed disappointment over the company's unchanged guidance but shared that the Binax COVID test could serve as a potential catalyst for growth. Cramer remains cautious, suggesting that while ABT holds promise, some AI stocks may offer higher returns with less risk.
Source: YAHOO